Drugs / A/H7N9
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03589807 | Aug 2018 → Jun 2020 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A/H7N9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03589807 ↗ |
| Modality | Vaccine | “Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine” NCT03589807 ↗ |
| Route | Intramuscular | “2017 A/H7N9 IIV administered intramuscularly” NCT03589807 ↗ |